Improved Therapy Response Assessment in Metastatic Brain Tumors

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 1, 2013

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2024

Conditions
Brain Metastases
Interventions
DIAGNOSTIC_TEST

Magnetic Resonance Imaging

Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.

RADIATION

Stereotactic Radiosurgery

A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.

DRUG

Ipilimumab, nivolumab or pembrolizumab

A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.

Trial Locations (1)

0424

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Hospital of Southern Norway Trust

OTHER

collaborator

Ostfold Hospital Trust

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

University Medical Center Groningen

OTHER

collaborator

University of Texas Southwestern Medical Center

OTHER

collaborator

South-Eastern Norway Regional Health Authority

OTHER

collaborator

Norwegian Cancer Society

OTHER

lead

Oslo University Hospital

OTHER

NCT03458455 - Improved Therapy Response Assessment in Metastatic Brain Tumors | Biotech Hunter | Biotech Hunter